Incanthera plc

About Incanthera plc

Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology. These deliver treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy. Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform. Current Focus: Incanthera’s Skincare Range The Company's current focus is a range of dermatological applications to meet currently unmet needs in the skincare market. Skin + CELL, Incanthera’s unique luxury skincare brand, brings scientifically proven formulations to cosmetics. Enriched with targeted bioactive B3 (an activated form of niacinamide) Skin + CELL’s unique formulations are delivered directly into the skin’s cells to optimise and protect cellular health, energy and protective capabilities. In June 2025, Incanthera announced an agreement with a global Direct to Consumer Marketing Agency to launch Skin + CELL across its platform, utilising its influencers and social media to raise awareness and to market the product and generate sales orders. Incanthera’s unique Skin + CELL range launched on 11 August 2025, with 100,000 units across the range, through targeted marketing campaigns utilising a global social media, influencer and ambassador network. Sales are completed via a dedicated Skin + CELL website, www.skinandcell.com designed to market and sell the full product range. The Company originated from the Institute of Cancer Therapeutics, University of Bradford and has a portfolio of specific cancer-targeting therapeutics through a pipeline agreement with the Institute of Cancer Therapeutics and other corporate acquisitions. Incanthera’s strategy is to develop or acquire each asset, technology and candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.